Eisai expands neglected disease interests through TB drug alliance
This article was originally published in Scrip
Executive Summary
Eisai has become the first Japanese pharmaceutical company to sign up to the Tuberculosis Drug Accelerator (TBDA), an international public-private partnership for the discovery of novel drugs against TB.